Bluejay DiagnosticsBJDX
BJDX
About: Bluejay Diagnostics Inc is a medical diagnostics company. It is developing rapid tests using whole blood using its Symphony technology platform to improve patient outcomes in critical care settings. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings and is a clinically established inflammatory biomarker for the assessment of the severity of infection and inflammation across many disease indications, including sepsis.
Employees: 10
0
Funds holding %
of 7,290 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
5.68% less ownership
Funds ownership: 6.14% [Q3] → 0.46% (-5.68%) [Q4]
69% less funds holding
Funds holding: 13 [Q3] → 4 (-9) [Q4]
91% less capital invested
Capital invested by funds: $129K [Q3] → $12.2K (-$117K) [Q4]
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 9
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Research analyst outlook
We haven’t received any recent analyst ratings for BJDX.
Financial journalist opinion
Neutral
GlobeNewsWire
3 months ago
Bluejay Diagnostics Announces Reverse Stock Split
ACTON, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced that the Company's Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-50 (the “Reverse Stock Split”). The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on November 18, 2024, and the Company's common stock will open for trading on The Nasdaq Capital Market on a post-split basis on November 18, 2024 under the Company's existing trading symbol, “BJDX.” At such time, the Company's common stock will also commence trading with a new CUSIP number, 095633509.
Neutral
GlobeNewsWire
8 months ago
Bluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public Offering
ACTON, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced the closing of a firm commitment underwritten public offering with gross proceeds to the Company expected to be approximately $8.75 million, before deducting underwriting discounts and other estimated expenses payable by the Company. The base offering consisted of 5,368,098 Common Units or Prefunded Units, each Unit consisting of one share of the Company's common stock (“Common Stock”) or one pre-funded warrant to purchase one share of Common Stock (each, a “Prefunded Warrant”), two Class C warrants each to purchase one share of our common stock (each, a “Class C Warrant”) and one Class D Warrant to purchase such number of shares of common stock as determined in the Class D Warrant (each, a “Class D Warrant” and together with the Class C Warrants, the “Common Warrants”). The purchase price of each Common Unit is $1.63, and the purchase price of each Prefunded Unit is $1.6299 (which is equal to the public offering price per Common Unit minus $0.0001). The Prefunded Warrants will be immediately exercisable and may be exercised at any time until all the Prefunded Warrants are exercised in full.
Neutral
GlobeNewsWire
8 months ago
SYMON-I Study of Symphony IL-6 Suggests Prediction of Mortality in Sepsis Patients
Results from primary analysis of the SYMON-I pilot clinical study consistent with IL-6 as a predictor of patients who have a mortality event with 28 days after sepsis and septic shock diagnosis and are admitted to the intensive care unit (ICU). Results from primary analysis of the SYMON-I pilot clinical study consistent with IL-6 as a predictor of patients who have a mortality event with 28 days after sepsis and septic shock diagnosis and are admitted to the intensive care unit (ICU).
Neutral
GlobeNewsWire
1 year ago
Bluejay Diagnostics Announces Closing of $3.5 Million Public Offering
ACTON, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced the closing of its previously announced public offering of 2,692,308 shares of the Company's common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 2,692,308 shares of common stock at a combined offering price of $1.30 per share (or pre-funded warrant in lieu thereof) and associated warrant. The warrants have an exercise price of $1.30 per share and are immediately exercisable upon issuance for a period of five years following the date of issuance.
Neutral
GlobeNewsWire
1 year ago
Bluejay Diagnostics Announces Pricing of $3.5 Million Public Offering
ACTON, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced the pricing of a public offering of 2,692,308 shares of the Company's common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 2,692,308 shares of common stock at a combined offering price of $1.30 per share (or pre-funded warrant in lieu thereof) and associated warrant. The warrants will have an exercise price of $1.30 per share and will be immediately exercisable upon issuance for a period of five years following the date of issuance. The closing of the offering is expected to occur on or about January 2, 2024, subject to the satisfaction of customary closing conditions.
Neutral
GlobeNewsWire
1 year ago
Bluejay Diagnostics, Inc. Announces Initiation of Multicenter Clinical Study Evaluating Symphony IL-6 in Sepsis Patients (SYMON Study)
This Study performs unique rapid on-site measurements of interleukin-6 (IL-6) and positions Company to move forward with multiple initiatives.
Charts implemented using Lightweight Charts™